Literature DB >> 10595268

Uptake of genetic testing and pre-test levels of mental distress in Norwegian families with known BRCA1 mutations.

J G Reichelt1, A A Dahl, K Heimdal, P Møller.   

Abstract

232 family members from 27 Norwegian families with BRCA1 mutations were offered genetic testing. 180/232 (78%) chose to be tested, 14/232 (6%) have not yet decided and 38/232 (16%) declined. All 232 persons were invited to fill in the following questionnaires when offered testing: Impact of Event Scale (IES), Hospital Anxiety and Depression Scale (HADS), General Health Questionnaire (GHQ-28) and Beck Hopelessness Scale (BHS). 207/232 (89%) responded to the questionnaires. Of those declining to be tested 23/38 (61%) answered the questionnaires compared to 170/180 (94%) of those wanting the test (p < 0.0001). A higher proportion of females with a history of cancer than females without such a history had abnormal scores on the IES-intrusion and GHQ questionnaires (p < 0.001). Healthy females who were deciding on predictive testing had the same or lower prevalence of mental distress compared to the general population, between 4.3% and 18.0% as measured by the different questionnaires. Males did not differ from healthy females on any of the measures. According to their HADS scores, women without a history of cancer deciding on predictive testing for breast-ovarian cancer had lower or equal levels of mental distress compared to the general population. The high uptake of genetic testing combined with the lower than normal prevalence of mental distress indicates that the activity may continue as practised, awaiting longitudinal data concerning the levels of mental distress after genetic testing.

Entities:  

Mesh:

Year:  1999        PMID: 10595268      PMCID: PMC3850804          DOI: 10.1155/1999/581346

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  9 in total

1.  Uptake of BRCA1 genetic testing in adult sisters and daughters of known mutation carriers in Norway.

Authors:  Trine Levin Bodd; Jon Reichelt; Ketil Heimdal; Pal Moller
Journal:  J Genet Couns       Date:  2003-10       Impact factor: 2.537

2.  A new scale measuring psychologic impact of genetic susceptibility testing for Alzheimer disease.

Authors:  Winston W Chung; Clara A Chen; L Adrienne Cupples; J Scott Roberts; Susan C Hiraki; Anil K Nair; Robert C Green; Robert A Stern
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jan-Mar       Impact factor: 2.703

3.  BRCA1 testing with definitive results: a prospective study of psychological distress in a large clinic-based sample.

Authors:  Jon G Reichelt; Ketil Heimdal; Pål Møller; Alv A Dahl
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

4.  Quality of life and its relation to cancer-related stress in women of families with hereditary cancer without demonstrated mutation.

Authors:  Amy Østertun Geirdal; Lovise Maehle; Ketil Heimdal; Astrid Stormorken; Pål Møller; Alv A Dahl
Journal:  Qual Life Res       Date:  2006-04       Impact factor: 4.147

5.  Intrusion and avoidance in subjects undergoing genetic investigation and counseling for hereditary cancer.

Authors:  Cathrine Bjorvatn; Geir Egil Eide; Berit R Hanestad; Anniken Hamang; Odd E Havik
Journal:  Support Care Cancer       Date:  2009-02-18       Impact factor: 3.603

6.  Men's values-based factors on prostate cancer risk genetic testing: a telephone survey.

Authors:  David J Doukas; Yuelin Li
Journal:  BMC Med Genet       Date:  2004-12-10       Impact factor: 2.103

7.  Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort.

Authors:  C Foster; D G R Evans; R Eeles; D Eccles; S Ashley; L Brooks; R Davidson; J Mackay; P J Morrison; M Watson
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

8.  Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.

Authors:  Trine Levin; Lovise Mæhle
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

9.  Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort.

Authors:  M Watson; C Foster; R Eeles; D Eccles; S Ashley; R Davidson; J Mackay; P J Morrison; P Hopwood; D G R Evans
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.